Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 May 4;28(11):1040–1047. doi: 10.1007/s11655-021-3512-5

Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration

Aditya Upadhayay 1, Gopal Patel 2, Dharm Pal 3, Awanish Kumar 1,✉
PMCID: PMC9065245  PMID: 35507298

Abstract

To date, no satisfactory treatment for COVID-19 is available. This review reported few recent updates regarding the drugs (allopathy/traditional medicines) used for the treatment of COVID-19 concerning clinical studies. Content of the article spotlight the contribution of allopathic and Ayurvedic drugs to the scientific basis for utilization as a potential therapy against COVID-19 infection and provide new insights on the integration of allopathy and traditional medicine. It advocated the combination of these two systems of treatment will ascertain their integrations, and there would be a good possibility and scope for developing a model of integration in the management of COVID-19. Provided discussion may help researchers, physicians, and healthcare policymakers to encourage for effective and integrated use of allopathic and Ayurvedic medicines to control the COVID-19 pandemic more effectively.

Keywords: COVID-19, allopathy, traditional medicine, integration, promising therapy

Acknowledgments

Authors are grateful to the National Institute of Technology, Raipur (CG), India and Zhejiang Chinese Medical University, PR China.

Author Contributions

Aditya U: information collection, design, writing manuscript draft; Gopal P: design, draft writing; Dharm P: design, draft writing; Awanish K: conceptulization, design, and finalize manuscript.

Footnotes

Conflict of Interest

All authors declare that they have no conflict of interest.

References

  • 1.Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18:271–278. doi: 10.1097/MCP.0b013e328351f8d4. [DOI] [PubMed] [Google Scholar]
  • 2.Singhal T. A review of coronavirus disease—2019 (COVID-19) Ind J Pediatr. 2020;87:281–286. doi: 10.1007/s12098-020-03263-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948. doi: 10.1016/j.ijantimicag.2020.105948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;24:9. doi: 10.3390/jcm9041225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, et al. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm. 2021;18:754–771. doi: 10.1021/acs.molpharmaceut.0c00608. [DOI] [PubMed] [Google Scholar]
  • 6.Kumar SU, Priya NM, Nithya SR, Kannan P, Jain N, Kumar DT, et al. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. Biotech. 2021;11:198. doi: 10.1007/s13205-021-02749-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21:343–360. doi: 10.1631/jzus.B2000083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens (Basel, Switzerland) 2020;9:337. doi: 10.3390/pathogens9050331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278. doi: 10.1126/science.1087139. [DOI] [PubMed] [Google Scholar]
  • 11.Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. J Med Virol. 2020;92:521–528. doi: 10.1002/jmv.25700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbes. 2020;27:325–328. doi: 10.1016/j.chom.2020.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–423. doi: 10.1002/jmv.25681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hussain S, Pan J, Chen Y, Yang Y, Xu J, Peng Y, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005;79:5288–5298. doi: 10.1128/JVI.79.9.5288-5295.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–569. doi: 10.1038/s41564-020-0688-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol. 2012;2:264–275. doi: 10.1016/j.coviro.2012.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13:667–673. doi: 10.1016/j.jiph.2020.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839. [DOI] [PubMed] [Google Scholar]
  • 22.Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: a multidisciplinary review. Public Health Front. 2020;8:383. doi: 10.3389/fpubh.2020.00383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Almaghaslah D, Kandasamy G, Almanasef M, Vasudevan R, Chandramohan S. Review on the coronavirus disease (COVID-19) pandemic: its outbreak and current status. Int J Clin. Pract. 2020;74:e13637. doi: 10.1111/ijcp.13637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wu R, Wang L, Kuo H-C, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;6:56–70. doi: 10.1007/s40495-020-00216-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155–166. doi: 10.1038/s41584-020-0372-x. [DOI] [PubMed] [Google Scholar]
  • 26.Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3:722–727. doi: 10.1016/S1473-3099(03)00806-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12:322–325. doi: 10.1093/jmcb/mjaa014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–73. doi: 10.5582/bst.2020.01047. [DOI] [PubMed] [Google Scholar]
  • 29.Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9e00221–18. [DOI] [PMC free article] [PubMed]
  • 30.Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295:4773–4779. doi: 10.1074/jbc.AC120.013056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020;40:416–437. doi: 10.1002/phar.2398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Villalaín J. Membranotropic effects of Arbidol, a broad antiviral molecule, on phospholipid model membranes. J Phys Chem B. 2010;114:8544–8554. doi: 10.1021/jp102619w. [DOI] [PubMed] [Google Scholar]
  • 33.Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad B: Phys Biol Sci. 2017;93:449–463. doi: 10.2183/pjab.93.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs. 2001;61:263–283. doi: 10.2165/00003495-200161020-00011. [DOI] [PubMed] [Google Scholar]
  • 35.Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769. doi: 10.2165/00003495-200363080-00004. [DOI] [PubMed] [Google Scholar]
  • 36.Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Kor Med Sci. 2020;35:e79. doi: 10.3346/jkms.2020.35.e79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Owa AB, Owa OT. Lopinavir/ritonavir use in COVID-19 infection: is it completely non-beneficial? J Microbiol Immunol Infect. 2020;53:674–675. doi: 10.1016/j.jmii.2020.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a clinician’s perspective. Diabetes Metab Syndr. 2020;14:971–978. doi: 10.1016/j.dsx.2020.06.054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango D, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia. PLoS One. 2021;16:e0252057. doi: 10.1371/journal.pone.0252057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020;26:243–250. doi: 10.1007/s11655-020-3192-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kazim M, Puri SK, Dutta GP, Narasimham MV. Evaluation of Ayush-64 for blood schizontocidal activity against rodent and simian malaria parasites. Ind J Malariol. 1991;28:255–258. [PubMed] [Google Scholar]
  • 42.Gundeti MS, Bhurke LW, Mundada PS, Murudkar S, Surve A, Sharma R, et al. Ayush 64, a polyherbal Ayurvedic formulation in influenza-like illness—results of a pilot study. J Ayurv Integr Med. 2020;S0975–9476:30025–5. doi: 10.1016/j.jaim.2020.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ganguly B, Umapathi V, Rastogi SK. Nitric oxide induced by Indian ginseng root extract inhibits infectious bursal disease virus in chicken embryo fibroblasts in vitro. J Anim Sci Technol. 2018;60:2. doi: 10.1186/s40781-017-0156-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Borse S, Joshi M, Saggam A, Bhat V, Walia S, Marathe A, et al. Ayurveda botanicals in COVID-19 management: an in silico multi-target approach. PLoS One. 2021;16:e0248479. doi: 10.1371/journal.pone.0248479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Balkrishna A, Raj P, Singh P, Varshney A. Influence of Patient-Reported treatment satisfaction on psychological health and quality of life among patients receiving Divya-Swasari-Coronil-Kit against COVID-19: findings from a cross-sectional “Satisfaction COVID” survey. Patient Prefer Adherence. 2021;15:899–909. doi: 10.2147/PPA.S302957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, et al. Antiviral effects of Glycyrrhiza species. Phytother Res. 2008;22:141–148. doi: 10.1002/ptr.2295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046. doi: 10.1016/S0140-6736(03)13615-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Sinha SK, Prasad SK, Islam MA, Gurav SS, Patil RB, AlFaris NA, et al. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. J Biomol Struct Dyn. 2021;39:4686–4700. doi: 10.1080/07391102.2020.1779132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Arora R, Chawla R, Marwah R, Arora P, Sharma RK, Kaushik V, et al. Potential of complementary and alternative medicine in preventive management of novel H1N1 flu (Swine Flu) pandemic: thwarting potential disasters in the bud. Evid Based Complement Alternat. 2011;2011:586506. doi: 10.1155/2011/586506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, et al. Diet, gut microbiota and COVID-19. Ind J Microbiol. 2020;60:1–10. doi: 10.1007/s12088-020-00908-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Patel SKS, Lee JK, Kalia VC. Deploying biomolecules as anti-COVID-19 agents. Ind J Microbiol. 2020;60:263–268. doi: 10.1007/s12088-020-00893-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70. doi: 10.1016/j.cytogfr.2020.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Gautam S, Gautam A, Chhetri S, Bhattarai U. Immunity against COVID-19: potential role of Ayush Kwath. J Ayurv Integr Med. 2022;13:100350. doi: 10.1016/j.jaim.2020.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Sachan S, Dhama K, Latheef SK, Samad HA, Mariappan AK, Munuswamy P, et al. Immunomodulatory potential of tinospora cordifolia and CpG ODN (TLR21 agonist) against the very virulent, infectious bursal disease virus in SPF chicks. Vaccines (Basel) 2019;7:106. doi: 10.3390/vaccines7030106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Qing GC, Zhang H, Bai Y, Luo Y. Traditional Chinese and Western medicines jointly beat COVID-19 pandemic. Chin J Integr Med. 2020;26:403–404. doi: 10.1007/s11655-020-3095-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61:2163–2175. doi: 10.2165/00003495-200161150-00002. [DOI] [PubMed] [Google Scholar]
  • 57.Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002;34:234–238. doi: 10.1086/324351. [DOI] [PubMed] [Google Scholar]

Articles from Chinese Journal of Integrative Medicine are provided here courtesy of Nature Publishing Group

RESOURCES